AI Ophthalmic Potential Target hospitals, clinics, and laboratories that perform diabetic retinopathy screening with AI-powered devices. Leverage partnerships with ophthalmology suppliers and digital ophthalmoscope manufacturers to co-market EyeStar-Bio solutions.

Neuropathy & Retinopathy Expand sales outreach to diabetes care programs and endocrinology departments focusing on early detection of diabetic retinopathy and diabetic peripheral neuropathy, aligning with NIH-funded clinical validation efforts.

Global Reach Highlight international deployments and contactless testing capabilities to appeal to global health networks, NGOs, and government health initiatives seeking scalable AI diagnostics.

NIH-Backed Validation Leverage ongoing NIH-supported grants and clinical validation studies as proof points to secure pilot deployments and expanded funding for commercialization in target markets.

Strategic Partnerships Pursue collaborations with major diagnostic and equipment players (for example digital ophthalmoscope manufacturers and medical device distributors) to accelerate adoption and broaden channel reach.